Program
deutetrabenazine
Also written as “SD-809”, “TEV-50717” and “Deutetrabenazine”.
Its studies are mostly in Tourette Syndrome · Huntington Disease · Tardive Dyskinesia · Cerebral Palsy, led by Teva Pharmaceutical Industries.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Teva Pharmaceutical Industries | 120 open or running | phase 4since May 15, 2026 | Feb 20, 2013 | none ahead |
Also a collaborator on its studies: nuvelution-ts-pharma-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 20, 2013First study: phase 3 study in ChoreaFirst studyNCT01795859 · 90 enrolled · United States, Australia, Canada
- Jun 14, 2013Phase 3 study in ChoreaNCT01897896 · 119 enrolled · United States, Australia, Canada
- Jul 18, 20142 phase 3 studies in Tardive DyskinesiaNCT02195700, NCT02198794
- Nov 12, 2014Phase 3 study in Tardive DyskinesiaNCT02291861 · 298 enrolled · United States, Czechia, Germany and more
- Feb 2, 2016Phase 1 study in Tourette SyndromeNCT02674321 · 23 enrolled · United States
- Feb 26, 2018Phase 3 study in Tourette SyndromeNCT03452943 · 119 enrolled · United States, Canada, Denmark and more
- Jun 12, 20182 phase 3 studies in Tourette SyndromeNCT03567291, NCT03571256
- Jan 22, 2019Phase 3 study in Cerebral PalsyNCT03813238 · 63 enrolled · United States, Belgium, Canada and more
- Dec 12, 2019Phase 3 study in Cerebral PalsyNCT04200352 · 44 enrolled · United States, Denmark, Israel and more
- May 15, 2026Phase 4 study in Huntington DiseaseNCT07601516 · 50 enrolled · China
TargetBeta
“Synaptic vesicular amine transporter inhibitor; Synaptic vesicular amine transporter inhibitor”ChEMBL 37, by rule
Other programs on SLC18A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lisdexamfetaminerule | Takeda | phase 4 | 47 |
| valbenazinerule | Neurocrine Biosciences | phase 4 | 28 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07601516Huntington Disease · China | 4 | Completed | Oct 24, 2025 | 50 |
| NCT04200352Cerebral Palsy · United States, Denmark, Israel and more | 3 | Terminated | Feb 14, 2023 | 44 |
| NCT03813238Cerebral Palsy · United States, Belgium, Canada and more | 3 | Completed | Jul 5, 2022 | 63 |
| NCT03571256Tourette Syndrome · United States, Argentina, Australia and more | 3 | Completed | Dec 9, 2019 | 158 |
| NCT03567291Tourette Syndrome · United States, Argentina, Australia and more | 3 | Terminated | May 15, 2020 | 228 |
| NCT03452943Tourette Syndrome · United States, Canada, Denmark and more | 3 | Completed | Nov 12, 2019 | 119 |
| NCT02674321Tourette Syndrome · United States | 1 | Completed | Jun 2015 | 23 |
| NCT02291861Tardive Dyskinesia · United States, Czechia, Germany and more | 3 | Completed | Aug 19, 2016 | 298 |
| NCT02198794Tardive Dyskinesia · United States, Czechia, Germany and more | 3 | Completed | Dec 6, 2019 | 343 |
| NCT02195700Tardive Dyskinesia · United States, Czechia, Poland and more | 3 | Completed | May 2015 | 117 |
| NCT01897896Chorea · United States, Australia, Canada | 3 | Completed | Aug 21, 2017 | 119 |
| NCT01795859Chorea · United States, Australia, Canada | 3 | Completed | Dec 5, 2014 | 90 |
How it is read
Names in the registry
- “SD-809”, 6 entries
- “TEV-50717”, 5 entries
- “Deutetrabenazine”, 1 entry
Codes read as this program: TEV50717.
Conditions, from the studies’ own filings
- Tourette Syndrome, 4 studies
- Huntington Disease, 3 studies
- Tardive Dyskinesia, 3 studies
- Cerebral Palsy, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.